Healthcare and Biotechnology in Slovakia: How to Unlock the Region's Hidden Potential with Private Capital and Investments

Slovakia and the wider Central and Eastern European (CEE) region are poised for significant advancements in healthcare and biotechnology.

The recent Biotech & Healthcare Investment Opportunities in Slovakia and CEE event, co-hosted by the American Chamber of Commerce and investment platform Crowdberry, underscored the region’s potential to emerge as a competitive force in this fast-growing sector.

With untapped talent, improving infrastructure, and access to EU funds, Slovakia’s healthcare and biotech landscape is ripe for growth—but collaboration of various sectors and private sector investments are crucial to fully realize its potential.

Europe’s Competitiveness at a Crossroads

Former European Central Bank President Mario Draghi’s report, The Future of European Competitiveness, paints a stark picture of Europe’s global standing. While the EU benefits from robust healthcare and education systems, its ability to convert these strengths into globally competitive industries lags behind the U.S. and China, with future trends looking even bleaker.

To reverse this trajectory, Europe must enhance its competitiveness by reducing bureaucratic barriers, simplifying regulations, and creating systemic support frameworks.

"One vital step to channel savings into productive investments and bolster economic resilience is establishing a European union of investments and savings," says Radim Dvořák, Acting Head of the European Commission in Slovakia. "In addition to that, it's crucial to address energy costs and secure supply chains to further strengthen the EU’s foundation. We should also not forget about forward-looking integration policies and talent retention which will fuel innovation and create ecosystems capable of attracting and nurturing global talent," continues